Bremer Trust National Association trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 6.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 37,379 shares of the biopharmaceutical company’s stock after selling 2,554 shares during the period. Bremer Trust National Association’s holdings in Pfizer were worth $1,354,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Peregrine Asset Advisers Inc. boosted its holdings in shares of Pfizer by 0.5% in the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 35 shares during the period. Northwest Quadrant Wealth Management LLC boosted its holdings in shares of Pfizer by 0.8% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares during the period. Stone House Investment Management LLC boosted its holdings in shares of Pfizer by 1.0% in the second quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 72 shares during the period. Highland Private Wealth Management boosted its holdings in shares of Pfizer by 0.8% in the second quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock worth $304,000 after acquiring an additional 76 shares during the period. Finally, Autus Asset Management LLC boosted its holdings in shares of Pfizer by 1.2% in the second quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 78 shares during the period. 71.41% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have recently commented on PFE shares. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a report on Friday, December 15th. UBS Group set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price target for the company in a report on Thursday, November 23rd. Finally, Morgan Stanley set a $41.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. Pfizer has an average rating of “Hold” and a consensus price target of $39.40.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter last year, the business posted $0.47 earnings per share. The company’s revenue for the quarter was up .6% on a year-over-year basis. equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd were given a dividend of $0.34 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date was Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.71%. Pfizer’s dividend payout ratio (DPR) is presently 77.71%.
Pfizer declared that its board has approved a stock buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
In other Pfizer news, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the sale, the director now owns 1,000 shares in the company, valued at $36,790. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. Insiders have sold 185,464 shares of company stock worth $6,767,939 in the last 90 days. Company insiders own 0.06% of the company’s stock.
WARNING: “Bremer Trust National Association Trims Holdings in Pfizer Inc. (PFE)” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/03/13/bremer-trust-national-association-trims-holdings-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.